Psychopharmacology Practice Questions

Q: Which antipsychotic drug is known for its effectiveness in managing schizophrenia but requires monitoring due to its risk of metabolic side effects?

Quetiapine. ***Quetiapine*** - **Quetiapine** is a **second-generation antipsychotic** effective for schizophrenia, but it is well-known for its metabolic side effects. - These side effects include **weight gain**, **dyslipidemia**, and **hyperglycemia**, necessitating careful metabolic monitoring. *Haloperidol* - **Haloperidol** is a **first-generation antipsychotic** primarily associated with **extrapyramidal symptoms (EPS)** and **tardive dyskinesia**, rather than significant metabolic disturbances. - While effective for psychosis, its side effect profile is distinct from metabolic concerns. *Risperidone* - **Risperidone** is a **second-generation antipsychotic** that also carries a risk of metabolic side effects, specifically **weight gain** and **hyperprolactinemia**. - However, **quetiapine** generally has a more pronounced risk of the full spectrum of metabolic syndrome compared to risperidone. *Chlorpromazine* - **Chlorpromazine** is a **first-generation antipsychotic** notable for **sedation**, **hypotension**, and **anticholinergic side effects**. - While it can cause some weight gain, its metabolic risk is not as prominent as that of certain second-generation antipsychotics like quetiapine.

Q: A patient with bipolar disorder is on valproate and presents with symptoms of lethargy, confusion, and elevated ammonia levels. What condition is most likely associated with these symptoms?

Hyperammonemia due to valproate use. ***Hyperammonemia due to valproate use*** - Valproate can inhibit the urea cycle, leading to impaired ammonia detoxification and subsequent hyperammonemia - Symptoms like lethargy and confusion are common manifestations of elevated ammonia levels, particularly in the absence of liver failure - This is a well-recognized adverse effect that can occur even with therapeutic valproate levels *Toxicity from lithium* - Lithium toxicity typically presents with symptoms such as tremor, polyuria, polydipsia, and potentially seizures or arrhythmias, which are not described here - While it can cause neurological symptoms, it is not directly associated with elevated ammonia levels *Toxicity from carbamazepine* - Carbamazepine toxicity often involves ataxia, nystagmus, and diplopia, and in severe cases, coma - It does not primarily lead to hyperammonemia; instead, it can cause hyponatremia or blood dyscrasias *Rash induced by lamotrigine* - Lamotrigine-induced rash is a dermatological manifestation, ranging from benign maculopapular rash to severe conditions like Stevens-Johnson syndrome - It does not cause lethargy, confusion, or elevated ammonia levels

Q: A 30-year-old female with a history of bipolar disorder presents with symptoms of acute mania. She is currently on lithium with therapeutic serum levels (0.8 mEq/L). What additional medication should be considered?

Consider adding valproate. ***Consider adding valproate*** - For acute mania that is not responding adequately to lithium monotherapy, **adding an antipsychotic or another mood stabilizer like valproate** is a common and effective strategy. - Valproate is particularly useful for **mixed episodes** and rapid cycling, but also effective for acute manic episodes. *Consider switching to carbamazepine* - While **carbamazepine** is an alternative mood stabilizer, switching from lithium would mean abandoning an agent that might still have some efficacy or therapeutic potential, especially if the patient previously responded well. - Adding a second agent rather than switching is generally preferred to address acute manic symptoms when monotherapy is insufficient. *Consider increasing lithium dose with monitoring* - The question implies the patient is already on lithium and experiencing breakthrough manic symptoms, suggesting the current dose or monotherapy is insufficient. **Increasing the lithium dose** might be considered, but only after checking current lithium levels to ensure they are subtherapeutic and within a safe range for upward titration. - **Lithium has a narrow therapeutic index**, and increasing the dose without careful monitoring could lead to toxicity. *Consider discontinuing lithium* - **Discontinuing lithium** would remove the existing mood stabilization and potentially worsen the manic symptoms or precipitate a more severe episode, especially given the patient's history of bipolar disorder. - Abrupt discontinuation of mood stabilizers is generally avoided due to the **risk of relapse**.

Q: A 28-year-old male with obsessive-compulsive disorder experiences minimal relief after an adequate trial of high-dose SSRIs. What is the next best treatment option?

Add clomipramine. ***Add clomipramine*** - **Clomipramine**, a tricyclic antidepressant (TCA), is a potent serotonin reuptake inhibitor and is considered an effective alternative for treatment-resistant OCD when SSRIs fail. - It can be used as monotherapy (after tapering the SSRI) or carefully as augmentation, though combination requires monitoring for serotonin syndrome. - Its efficacy in OCD is well-established in clinical trials, making it a valid option for SSRI non-responders. *Start electroconvulsive therapy* - **Electroconvulsive therapy (ECT)** is generally reserved for severe, treatment-resistant depression with psychotic features or catatonia. - While it has been explored in very refractory OCD cases after multiple medication failures, it is not a standard next-line treatment given the available pharmacological options. *Switch to antipsychotics* - **Antipsychotic monotherapy** is not indicated for OCD treatment. - However, **augmentation** with low-dose atypical antipsychotics (aripiprazole, risperidone) added to SSRIs is an evidence-based strategy for partial responders, but the option states "switch" rather than "add." - Direct switching to antipsychotics as monotherapy would be inappropriate. *Add benzodiazepines* - **Benzodiazepines** may provide short-term relief of severe anxiety symptoms or insomnia associated with OCD. - They do not address the core obsessive-compulsive symptoms and are not considered an effective augmentation strategy for the primary treatment of OCD. - They carry risks of dependence and tolerance with long-term use.

Q: A 25-year-old female with obsessive-compulsive disorder has not responded to 8 weeks of sertraline 50mg daily. What is the next step in pharmacotherapy?

Increase the dose of SSRIs. ***Increase the dose of SSRIs*** - For **OCD**, **SSRIs** often require **higher doses** (typically 2-3 times higher than for depression) and longer treatment durations to achieve a therapeutic effect. - **Sertraline 50mg is subtherapeutic** for OCD; the therapeutic range is **150-200mg daily** (up to 200mg maximum). - Since the current dose is inadequate despite appropriate duration (8 weeks), **dose optimization is the most appropriate next step** before considering other interventions. *Switch to a different class of antidepressant* - **SSRIs** are considered **first-line pharmacotherapy** for OCD, and switching to a different antidepressant class is typically reserved for cases where multiple SSRI trials at adequate doses and duration have failed. - This option is premature before optimizing the current SSRI dosage. *Start psychotherapy* - **Cognitive Behavioral Therapy (CBT)**, especially **Exposure and Response Prevention (ERP)**, is a highly effective treatment for OCD and is often recommended alongside medication. - While beneficial, the question specifically asks for the "next step in **pharmacotherapy**," implying a drug-related intervention. *Add an antipsychotic* - Augmentation with an **antipsychotic** (e.g., risperidone, aripiprazole) is usually considered when there has been a partial or non-response to **adequate trials of high-dose SSRIs** (typically after 2-3 SSRI trials at therapeutic doses). - This step is too aggressive given that the initial SSRI dose was not optimized.

Q: A 19-year-old male with a history of bipolar disorder presents with elevated mood, increased energy, and decreased need for sleep for the past week. Which medication is most appropriate for acute management?

Olanzapine. ***Olanzapine*** - **Second-generation antipsychotics** (SGAs) like olanzapine are **first-line agents** for the **acute management of manic episodes**, particularly when there is severe agitation or psychotic features. - Olanzapine provides **rapid control of agitation and behavioral symptoms**, often showing improvement within 24-48 hours, which is crucial in an acute setting. - SGAs are particularly useful when **immediate sedation** and symptom control are needed. *Lithium* - **Lithium** is a highly effective **mood stabilizer** for bipolar disorder and is considered a first-line maintenance agent. - However, its therapeutic effects for acute mania take **1-2 weeks** to fully manifest, making it less ideal for immediate acute symptom control. - It also requires careful **monitoring of blood levels** due to a narrow therapeutic window and potential for toxicity. *Fluoxetine* - **Fluoxetine** is an **antidepressant (SSRI)** and is **contraindicated as monotherapy** in acute mania due to the high risk of **inducing or worsening manic symptoms**. - While it can be used cautiously in combination with a mood stabilizer for bipolar depression, it is inappropriate and potentially harmful for acute mania. *Valproate* - **Valproate** is also a **first-line agent** for acute mania and is equally effective as SGAs in many cases, with onset of antimanic effects typically within **4-5 days**. - In this clinical scenario, **olanzapine may be slightly preferred** due to more rapid initial control of agitation and behavioral symptoms in the first 24-48 hours, which is important for acute management. - Valproate is an excellent choice, particularly for less severe mania or when antipsychotic side effects are a concern.

Q: A patient diagnosed with bipolar disorder is on lithium therapy and presents with coarse tremors, polyuria, and confusion. What is the most appropriate next step?

Discontinue lithium therapy. ***Discontinue lithium therapy*** - The patient presents with **coarse tremors, polyuria, and confusion** - classical signs of **lithium toxicity**. - **Immediate discontinuation** of lithium is the priority to prevent progression to severe toxicity (seizures, renal failure, coma). - In symptomatic lithium toxicity, **stopping the drug takes precedence** over diagnostic confirmation. - **Serum lithium levels should be checked simultaneously**, but this should not delay stopping the medication. - Supportive care including **hydration and monitoring** should be initiated immediately. *Check serum lithium levels* - While checking serum levels is important for **confirming the diagnosis and guiding further management**, it should not delay discontinuation. - Levels help determine severity and need for **hemodialysis** (typically if >4 mEq/L with severe symptoms). - This is an essential step but is done **concurrently with**, not **instead of**, stopping lithium. *Increase the dose of lithium therapy* - This would dangerously **exacerbate lithium toxicity** and could lead to life-threatening complications. - Completely contraindicated in a patient showing clear signs of toxicity. *Switch to valproate therapy* - While valproate is an alternative mood stabilizer, switching therapy is **not the immediate priority** in acute toxicity. - The urgent concern is **managing the current toxicity**, not replacing the mood stabilizer. - Alternative treatments can be considered after the patient stabilizes.

Q: A 40-year-old woman with a history of bipolar disorder presents with increased energy, decreased need for sleep, and grandiose ideas. She has been taking lithium for several years. What is the most appropriate management?

Add an atypical antipsychotic. ***Add an atypical antipsychotic*** - The patient is experiencing a **manic episode** despite being on long-term lithium, indicating **breakthrough symptoms**. - Adding an **atypical antipsychotic** like olanzapine, quetiapine, or risperidone is an effective strategy for acute mania in patients already on a mood stabilizer. *Increase the lithium dose* - While adjusting lithium levels might be considered, simply increasing the dose may not be sufficient for an acute manic episode, especially if the patient is already at a therapeutic or near-therapeutic level. - Higher doses also carry an increased risk of **lithium toxicity**. *Switch to valproate* - Switching medications abruptly can destabilize the patient further, especially if lithium has been partially effective for a long period. - Adding an additional agent rather than switching is generally preferred for breakthrough symptoms to avoid a period of being unmedicated or inadequately medicated. *Discontinue lithium* - Discontinuing lithium can lead to a **rebound manic episode** or worsening of current symptoms, as it is an effective mood stabilizer. - It would be inappropriate to remove a medication that has been part of a long-term maintenance regimen during an acute exacerbation.

Q: A 30-year-old man with schizophrenia develops persistent involuntary movements of the face and tongue after long-term use of antipsychotics. What is the diagnosis?

Tardive dyskinesia. ***Tardive dyskinesia*** - This condition is characterized by **involuntary movements of the face and tongue**, often appearing after **long-term use of antipsychotic medications**. - Its **persistent nature** differentiates it from other extrapyramidal symptoms, as it often continues even after discontinuing the offending drug. *Parkinsonism* - This typically presents with a **triad of symptoms**: **bradykinesia**, **rigidity**, and **tremor**, which are not the primary features described here. - While it can be drug-induced, it typically manifests differently than the described **oro-facial dyskinesia**. *Akathisia* - This involves a feeling of **inner restlessness** and a compelling need to **move**, often manifesting as pacing or rocking. - It does not involve the specific involuntary movements of the face and tongue observed in the patient. *Acute dystonia* - This is characterized by **sudden, sustained muscle contractions** leading to **abnormal postures or movements**, often occurring soon after starting or increasing an antipsychotic dose. - Unlike tardive dyskinesia, these dystonic reactions are typically **acute** and resolve with specific treatments like anticholinergics.

Q: A 30-year-old male with schizophrenia who has been stable on antipsychotic medication now presents with muscle stiffness, fever, and confusion. What is the most likely diagnosis?

Neuroleptic malignant syndrome. ***Neuroleptic malignant syndrome*** - The combination of **muscle rigidity**, **fever (hyperthermia)**, and **altered mental status (confusion)** in a patient on antipsychotic medication is a classic presentation of **neuroleptic malignant syndrome (NMS)**. - NMS is a **life-threatening idiosyncratic reaction** to antipsychotic drugs, characterized by **autonomic dysfunction** (e.g., labile blood pressure, tachycardia) and often elevated **creatine kinase (CK)** levels. *Serotonin syndrome* - This syndrome typically results from an excess of **serotonergic activity**, often due to drug interactions (e.g., SSRIs with MAOIs) or overdose. - While it can present with fever and altered mental status, it is more commonly associated with **hyperreflexia**, **clonus**, and myoclonus, rather than severe rigidity, and is not usually triggered by antipsychotics alone. *Malignant hyperthermia (triggered by anesthetics)* - **Malignant hyperthermia** is a genetic disorder primarily triggered by **volatile anesthetic agents** (e.g., halothane, succinylcholine) during surgery. - Its clinical presentation, though similar with hyperthermia and muscle rigidity, is specific to perioperative exposure to these particular drugs, which is not indicated in this case. *Acute dystonia* - **Acute dystonia** is an extrapyramidal symptom (EPS) characterized by **sustained involuntary muscle contractions**, leading to abnormal posturing or repetitive movements. - While it can occur shortly after initiating or increasing antipsychotic medication, it typically presents as specific muscle spasms (e.g., torticollis, oculogyric crisis) and does **not involve fever or significant altered mental status**.

Question 1

Which antipsychotic drug is known for its effectiveness in managing schizophrenia but requires monitoring due to its risk of metabolic side effects?

Accepted Answer

Quetiapine

Answer

Haloperidol

Answer

Risperidone

Answer

Chlorpromazine

Question 2

A patient with bipolar disorder is on valproate and presents with symptoms of lethargy, confusion, and elevated ammonia levels. What condition is most likely associated with these symptoms?

Accepted Answer

Hyperammonemia due to valproate use

Answer

Toxicity from lithium

Answer

Toxicity from carbamazepine

Answer

Rash induced by lamotrigine

Question 3

A 30-year-old female with a history of bipolar disorder presents with symptoms of acute mania. She is currently on lithium with therapeutic serum levels (0.8 mEq/L). What additional medication should be considered?

Accepted Answer

Consider adding valproate

Answer

Consider switching to carbamazepine

Answer

Consider increasing lithium dose with monitoring

Answer

Consider discontinuing lithium

Question 4

A 28-year-old male with obsessive-compulsive disorder experiences minimal relief after an adequate trial of high-dose SSRIs. What is the next best treatment option?

Accepted Answer

Add clomipramine

Answer

Start electroconvulsive therapy

Answer

Switch to antipsychotics

Answer

Add benzodiazepines

Question 5

A 25-year-old female with obsessive-compulsive disorder has not responded to 8 weeks of sertraline 50mg daily. What is the next step in pharmacotherapy?

Accepted Answer

Increase the dose of SSRIs

Answer

Switch to a different class of antidepressant

Answer

Start psychotherapy

Answer

Add an antipsychotic

Question 6

A 19-year-old male with a history of bipolar disorder presents with elevated mood, increased energy, and decreased need for sleep for the past week. Which medication is most appropriate for acute management?

Accepted Answer

Olanzapine

Answer

Lithium

Answer

Fluoxetine

Answer

Valproate

Question 7

A patient diagnosed with bipolar disorder is on lithium therapy and presents with coarse tremors, polyuria, and confusion. What is the most appropriate next step?

Accepted Answer

Discontinue lithium therapy

Answer

Check serum lithium levels

Answer

Increase the dose of lithium therapy

Answer

Switch to valproate therapy

Question 8

A 40-year-old woman with a history of bipolar disorder presents with increased energy, decreased need for sleep, and grandiose ideas. She has been taking lithium for several years. What is the most appropriate management?

Accepted Answer

Add an atypical antipsychotic

Answer

Increase the lithium dose

Answer

Switch to valproate

Answer

Discontinue lithium

Question 9

A 30-year-old man with schizophrenia develops persistent involuntary movements of the face and tongue after long-term use of antipsychotics. What is the diagnosis?

Accepted Answer

Tardive dyskinesia

Answer

Parkinsonism

Answer

Akathisia

Answer

Acute dystonia

Question 10

A 30-year-old male with schizophrenia who has been stable on antipsychotic medication now presents with muscle stiffness, fever, and confusion. What is the most likely diagnosis?

Accepted Answer

Neuroleptic malignant syndrome

Answer

Malignant hyperthermia (triggered by anesthetics)

Answer

Serotonin syndrome

Answer

Acute dystonia

Psychopharmacology — MCQs

Psychopharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?